...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Nonsuper-selective venous sampling for persistent hyperparathyroidism using a systemic hypocalcemic challenge
【24h】

Nonsuper-selective venous sampling for persistent hyperparathyroidism using a systemic hypocalcemic challenge

机译:使用系统性低钙血症挑战进行持续性甲状旁腺功能亢进的非超选择性静脉取样

获取原文
获取原文并翻译 | 示例

摘要

To describe a new protocol employing an acute systemic hypocalcemic challenge (SHC) aimed at augmenting the parathyroid hormone (PTH) gradient to enable nonsuper-selective venous sampling (VS) in patients with persistent primary hyperparathyroidism (PHPT). In a retrospective study, 37 patients (39 studies20 SHC, 19 super-selective VS) who underwent VS for persistent or recurrent PHPT were examined. Study patients were pretreated with intravenous hydration, diuretics, and bicarbonate to induce temporary relative hypocalcemia and then underwent nonsuper-selective VS targeted at large vessels within the neck and chest with rapid PTH testing. The traditional VS protocol involved super-selective VS with arteriography. SHC decreased ionized calcium by 0.098 mmol/L ± 0.18 (P = .07) and increased peripheral PTH by 10.2 pg/mL (P = .58). Positive VS gradients, defined as a < 1.4-fold difference from baseline to after SHC, were detected in 95% of patients. VS findings guided successful surgery in 77% of SHC cases and 90% of super-selective VS cases; the peak gradient site was concordant with operative findings in 46% of SHC cases and 80% of super-selective VS cases. Avoidance of super-selective sampling decreased mean fluoroscopy time from 91 minutes to 33 minutes and decreased contrast material administered from 204 mL to 63 mL (both P < .0001). The SHC protocol to enable nonsuper-selective VS in patients with persistent PHPT had the same ability as super-selective VS to detect a positive (< 1.4-fold) PTH gradient, was associated with decreased accuracy in identifying the site of the adenoma compared with super-selective VS, and significantly decreased contrast material used and fluoroscopy time.
机译:描述一种采用急性全身低钙血症激发(SHC)的新方案,旨在增强甲状旁腺激素(PTH)梯度,以使持续性原发性甲状旁腺功能亢进症(PHPT)患者能够进行非超选择性静脉采样(VS)。在一项回顾性研究中,检查了37例因持续或复发性PHPT而行VS的患者(39项研究20 SHC,19例超选择性VS)。研究患者接受了静脉水合作用,利尿剂和碳酸氢盐的预处理,以引起暂时的相对低血钙症,然后通过快速的PTH测试对颈部和胸部大血管进行了非超选择性VS。传统的VS协议涉及带有动脉造影的超选择性VS。 SHC使离子钙降低0.098 mmol / L±0.18(P = .07),并使外周血PTH增加10.2 pg / mL(P = .58)。在95%的患者中检测到阳性VS梯度,定义为从基线到SHC后的<1.4倍差异。 VS结果指导77%的SHC患者和90%的超选择性VS患者成功手术。在46%的SHC患者和80%的超选择性VS患者中,峰值梯度部位与手术结果一致。避免超选择性采样将平均透视时间从91分钟减少到33分钟,并且将造影剂的使用时间从204 mL减少到63 mL(均P <.0001)。 SHC协议可在持续性PHPT患者中启用非超选择性VS,与超选择性VS具有相同的检测正PTH梯度(<1.4倍)梯度的能力,与识别腺瘤部位的准确性相比,降低了超选择性VS,大大降低了使用的对比剂和荧光检查时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号